These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24289727)

  • 21. Serelaxin and acute heart failure.
    Tietjens J; Teerlink JR
    Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relaxin: a novel agent for the treatment of acute heart failure.
    Wilson SS; Ayaz SI; Levy PD
    Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
    Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
    Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis.
    Yu L; Cao L; Sun J; Li Z; Yao F; Zhou Y
    Medicine (Baltimore); 2018 Jun; 97(25):e11010. PubMed ID: 29923986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
    Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
    J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
    Schmieder RE; Mitrovic V; Hengstenberg C
    Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.
    Bani D
    Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives.
    Almeida-Pinto N; Dschietzig TB; Brás-Silva C; Adão R
    Clin Res Cardiol; 2024 Aug; 113(8):1137-1150. PubMed ID: 37721595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
    Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
    Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serelaxin for the treatment of heart failure.
    Moin DS; Bloom MW; Papadimitriou L; Butler J
    Expert Rev Cardiovasc Ther; 2016 Jun; 14(6):667-75. PubMed ID: 27045761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Odds still favor Novartis heart failure drug Serelaxin.
    Ratner M
    Nat Biotechnol; 2014 Jul; 32(7):602-3. PubMed ID: 25004210
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
    Loungani RS; Teerlink JR; Metra M; Allen LA; Butler J; Carson PE; Chen CW; Cotter G; Davison BA; Eapen ZJ; Filippatos GS; Gimpelewicz C; Greenberg B; Holbro T; Januzzi JL; Lanfear DE; Pang PS; Piña IL; Ponikowski P; Miller AB; Voors AA; Felker GM
    JACC Heart Fail; 2020 Dec; 8(12):999-1008. PubMed ID: 33189635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
    Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
    J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
    Dahlke M; Halabi A; Canadi J; Tsubouchi C; Machineni S; Pang Y
    J Clin Pharmacol; 2016 Apr; 56(4):474-83. PubMed ID: 26239266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First clinical experience with intravenous recombinant human relaxin in compensated heart failure.
    Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
    Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [What is new in the medical management of acute heart failure?].
    Meyer P; White M; Keller RF; Lerch R; Hullin R
    Rev Med Suisse; 2010 Jun; 6(252):1211-7. PubMed ID: 20614757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial.
    Pang PS; Teerlink JR; Voors AA; Ponikowski P; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Kriger J; Prescott MF; Hua TA; Severin T; Metra M
    JACC Heart Fail; 2016 Jul; 4(7):591-599. PubMed ID: 27039129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editor's Choice-Recent therapeutic trials on fluid removal and vasodilation in acute heart failure.
    Ennezat PV; Stewart M; Samson R; Bouabdallaoui N; Maréchaux S; Banfi C; Bouvaist H; Le Jemtel TH
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):86-95. PubMed ID: 25414321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.